España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Bristol-Myers Squibb
BMY
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$58.87
0.64
1.10%
At close: -
$58.83
-0.04
-0.07%
After Hours: 5:19 PM EDT
Get Report
Comment
Bristol-Myers Squibb (BMY) Forecast
News
Earnings
Bristol-Myers Squibb (BMY) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Bristol-Myers Squibb (NYSE:BMY) Stock
Bristol-Myers Squibb Stock (NYSE: BMY)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, November 18, 2024
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Vandana Singh
Friday, November 15, 2024
Shares of pharmaceutical companies are tradin...
Benzinga Newsdesk
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Vandana Singh
Committee For Medicinal Products For Human Us...
Benzinga Newsdesk
Wolfe Research Initiates Coverage On Bristol-...
Benzinga Newsdesk
Wednesday, November 13, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Vandana Singh
Tuesday, November 12, 2024
Citigroup Maintains Neutral on Bristol-Myers ...
Benzinga Newsdesk
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Vandana Singh
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Avi Kapoor
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Vandana Singh
BMO Capital Maintains Market Perform on Brist...
Benzinga Newsdesk
Morgan Stanley Maintains Underweight on Brist...
Benzinga Newsdesk
Leerink Partners Upgrades Bristol-Myers Squib...
Benzinga Newsdesk
Monday, November 11, 2024
What's Going On With Bristol-Myers Squibb Shares Monday?
Dylan Berman
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
Vandana Singh
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Vandana Singh
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
Vandana Singh
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
Avi Kapoor
Bristol-Myers Squibb shares are trading highe...
Benzinga Newsdesk
Bristol Myers Squibb To Showcase Cardiovascul...
Benzinga Newsdesk
Friday, November 08, 2024
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Vandana Singh
Wednesday, November 06, 2024
Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
Vandana Singh
Monday, November 04, 2024
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
Vandana Singh
How Is The Market Feeling About Bristol-Myers Squibb?
Benzinga Insights
Friday, November 01, 2024
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Vandana Singh
BMO Capital Maintains Market Perform on Brist...
Benzinga Newsdesk
Thursday, October 31, 2024
Bristol Myers Squibb Announced Topline Data F...
Benzinga Newsdesk
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Piero Cingari
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Vandana Singh
Bristol-Myers Squibb shares are trading highe...
Benzinga Newsdesk
Bristol Myers Squibb Expects 2024 Revenue Gro...
Benzinga Newsdesk
Bristol Myers Squibb Forecasts 2024 Adjusted ...
Benzinga Newsdesk
Bristol-Myers Squibb Q3 2024 Adj EPS $1.80 Be...
Benzinga Newsdesk
Wednesday, October 30, 2024
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Vandana Singh
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Vandana Singh
Monday, October 28, 2024
Bristol Myers Shares New Data on COBENFY for ...
Benzinga Newsdesk
Friday, October 25, 2024
Citigroup Downgrades Bristol-Myers Squibb to ...
Benzinga Newsdesk
Wednesday, October 23, 2024
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
Benzinga Insights
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
Vandana Singh
Why Is Evotec Stock Gaining Today?
Nabaparna Bhattacharya
Redwire Announced That It Is Launching An Inv...
Benzinga Newsdesk
Evotec And Bristol Myers Squibb Strengthen Pr...
Benzinga Newsdesk
Friday, October 18, 2024
Cantor Fitzgerald Reiterates Neutral on Brist...
Benzinga Newsdesk
Thursday, October 17, 2024
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Vandana Singh
Bernstein Initiates Coverage On Bristol-Myers...
Benzinga Newsdesk
Friday, October 11, 2024
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Vandana Singh
Wednesday, October 09, 2024
UBS Maintains Neutral on Bristol-Myers Squibb...
Benzinga Newsdesk
Monday, October 07, 2024
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
Zacks
Barclays Maintains Underweight on Bristol-Mye...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch